Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 16/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158150 | 0.92 | EGLN1 (0.49) | EGLN1 | |
| SCHEMBL6160407 | 0.91 | EGLN1 (0.51) | EGLN1 | |
| SCHEMBL6162365 | 0.86 | EGLN1 (0.42) | EGLN1 | |
| SCHEMBL6164431 | 0.85 | EGLN1 (0.49) | EGLN1HTTMLNRMMP2MMP1 | |
| SCHEMBL6160356 | 0.83 | EGLN1 (0.46) | EGLN1HTTMLNRMMP2MMP1 | |
| SCHEMBL6161195 | 0.80 | EGLN1 (0.46) | EGLN1HTTMLNRMMP2MMP1 | |
| SCHEMBL6160758 | 0.79 | EGLN1 (0.51) | EGLN1HTTMLNRMMP2MMP1 | |
| SCHEMBL6160360 | 0.79 | EGLN1 (0.46) | EGLN1HTTMLNRMMP2MMP1 | |
| SCHEMBL6158633 | 0.79 | EGLN1 (0.44) | EGLN1HTTMLNRMMP2MMP1 | |
| SCHEMBL6158886 | 0.78 | EGLN1 (0.48) | EGLN1HTTMLNRMMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | claimed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TAKEDA PHARMACEUTICALS NORTH AMERICA, INC. | 2005-07-28 | — | — | US | disclosed |
| EP-1500658-A1 | NOVEL THIOL DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165064-A1 | Novel thiol derivative, process for producing the same and use thereof | TST, QSOX1, MMP1 | EGLN1 841/4885HTT 581/4885MLNR 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.